AtriCure Q3 2024: revenue $115.9M (+17.9%), loss $0.17/sh, positive cash flow $16.3M

AtriCure, Inc.

2024-Q3 EPS reported -$0.62 revenue$341,030,000

Worldwide revenue $115.9M, up 17.9% YoY; U.S. $95.5M (+16.8%), Intl $20.5M (+23.3%).
Net loss per share $0.17 vs $0.20 YoY; adjusted EBITDA $7.9M, up $3.2M from Q3 2023.
Gross margin 74.9%, down 27 bps YoY due to unfavorable product/geographic mix.
Generated $16.3M cash flow from operations in the quarter.
Launched new products; growth driven by open ablation, appendage management, and pain management.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.